BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 7027859)

  • 1. Renal and electrolyte disturbances associated with cisplatin.
    Blachley JD; Hill JB
    Ann Intern Med; 1981 Nov; 95(5):628-32. PubMed ID: 7027859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer.
    Lee YK; Shin DM
    Korean J Intern Med; 1992 Jul; 7(2):118-21. PubMed ID: 1339077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
    Somlo G; Doroshow JH; Lev-Ran A; Ahn DC; Hwang L; Raschko JW; Forman SJ; Margolin KA; Morgan RJ; Leong LA
    J Clin Oncol; 1995 May; 13(5):1231-7. PubMed ID: 7738626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
    Goren MP
    Med Pediatr Oncol; 2003 Sep; 41(3):186-9. PubMed ID: 12868117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal salt wasting in patients treated with cisplatin.
    Hutchison FN; Perez EA; Gandara DR; Lawrence HJ; Kaysen GA
    Ann Intern Med; 1988 Jan; 108(1):21-5. PubMed ID: 3337511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing the impact of magnesium and potassium-supplemented hydration with cisplatin and the subsequent electrolyte replacement requirements.
    Uhm SJ; Meszaros E; Hammonds K; Patel I; Herrington JD
    J Oncol Pharm Pract; 2021 Jul; 27(5):1125-1131. PubMed ID: 32799780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persisting renotubular sequelae after cisplatin in children and adolescents.
    Bianchetti MG; Kanaka C; Ridolfi-Lüthy A; Hirt A; Wagner HP; Oetliker OH
    Am J Nephrol; 1991; 11(2):127-30. PubMed ID: 1951473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.
    Ries F; Klastersky J
    Am J Kidney Dis; 1986 Nov; 8(5):368-79. PubMed ID: 3538860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
    JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pseudoparalysis induced by cancer chemotherapy (cis-platinum)].
    Leclercq B; Escudier B; Tandonnet F; Conscience G; Roussignol E; Nitenberg G
    Cah Anesthesiol; 1985; 33(1):23-4. PubMed ID: 4039623
    [No Abstract]   [Full Text] [Related]  

  • 17. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
    Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
    J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnesium depletion enhances cisplatin-induced nephrotoxicity.
    Lajer H; Kristensen M; Hansen HH; Nielsen S; Frøkiaer J; Ostergaard LF; Christensen S; Daugaard G; Jonassen TE
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):535-42. PubMed ID: 15947931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
    Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
    PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.